From the American Academy of Ophthalmology

This multicenter, randomized, controlled trial evaluated whether a higher dose of ranibizumab (2.0 mg) could improve visual acuity and anatomy in 87 patients with persistent disease despite chronic monthly 0.5-mg ranibizumab injections. A higher dose resulted in statistically significant improvements in visual acuity and quantitative OCT measurements immediately after three consecutive monthly injections in patients with persistent intraretinal, subretinal or subretinal pigment epithelial fluid. Many patients also experienced qualitative improvements in anatomy as visualized by SD-OCT scans. Ophthalmology, February 2013